Historical and pathological overview of Castleman disease

Nishimura, M.; Nishimura, Yoshito; Nishikori, Asami; Yoshino, Tadashi; Sato, Yasuharu

doi:10.3960/jslrt.21036

Cited by 18 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, IPL maintains its distinctiveness as an independent entity, corresponding to plasma cell-type idiopathic MCD, not otherwise specified, 25 in the diverse disease concepts of MCD today ( Figure 1H ) 22 , 26 and even in the evolving concept ( Figure 1I ). 27 Kojima, who passed away at 62 in 2018, would have felt the same way and hoped to keep the concept of IPL from fading away so that researchers worldwide could revisit it.…”

Section: Conclusive Remarksmentioning

confidence: 99%

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980

Takeuchi

2022

JCEH

View full text Add to dashboard Cite

The current consensus on Castleman disease is that it is a group of several distinct lymphoproliferative disorders with different underlying pathogenesis and clinical outcomes. In 1980, Mori et al . proposed the concept of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL), a disease of unknown etiology, characterized by severe polyclonal hypergammaglobulinemia and generalized superficial lymphadenopathy. After Frizzera et al .’s landmark report in 1983, the term multicentric Castleman disease (MCD) gradually became established, and for a time, IPL was regarded as identical to MCD. However, with the subsequent recognition of human herpesvirus 8 (HHV8)-related MCD in the 1990s and the contributions by Kojima et al . in the 2000s, in which non-HHV8-related MCD (now called idiopathic MCD) was at least subclassified into IPL and others (non-IPL), it is now clear that the original distinctiveness of IPL is still maintained in MCD, which is a diverse collection of diseases.

show abstract

Section: Conclusive Remarksmentioning

confidence: 99%

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980

Takeuchi

2022

JCEH

View full text Add to dashboard Cite

show abstract

“…iMCD is a rare lymphoproliferative disorder that is characterized by multiple lymphadenopathies with unknown etiology [ 17 ]. In particular, iMCD-NOS is a heterogenous entity, likely including undefined disease [ 11 , 18 , 19 , 20 , 21 ]. The present results show that IPL is likely to be a separate subtype of iMCD, along with iMCD-TAFRO and iMCD-NOS, given its unique clinicopathological characteristics.…”

Section: Discussionmentioning

confidence: 99%

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease

Nishikori

Nishimura

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease that is not related to KSHV/HHV8 infection. Currently, iMCD is classified into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) and iMCD-NOS (not otherwise specified). The former has been established as a relatively homogeneous disease unit that has been recently re-defined, while the latter is considered to be a heterogeneous disease that could be further divided into several subtypes. In 1980, Mori et al. proposed the concept of idiopathic plasmacytic lymphadenopathy (IPL), a disease presenting with polyclonal hypergammaglobulinemia and a sheet-like proliferation of mature plasma cells in the lymph nodes. Some researchers consider IPL to be a part of iMCD-NOS, although it has not been clearly defined to date. This is the first paper to analyze iMCD-NOS clinicopathologically, to examine whether IPL forms a uniform disease unit in iMCD. Histologically, the IPL group showed prominent plasmacytosis and the hyperplasia of germinal centers, while the non-IPL group showed prominent vascularity. Clinically, the IPL group showed significant thrombocytosis and elevated serum IgG levels compared to the non-IPL group (p = 0.007, p < 0.001, respectively). Pleural effusion and ascites were less common in the IPL group (p < 0.001). The IPL group was more likely to have an indolent clinical course and a good response to the anti-IL-6 receptor antibody, while the non-IPL counterpart frequently required more aggressive medical interventions. Thus, the IPL group is a clinicopathologically uniform entity that forms an independent subtype of iMCD.

show abstract

“…Throughout its history, MCD has encompassed a wide variety of diseases based on similarities in lymph node histology [ 28 , 32 ]. We propose that disorders with a defined concept, such as POEMS syndrome [ 25 ] and TAFRO syndrome [ 20 , 21 ], should be separated from the MCD category.…”

Section: Relationship Between Tafro Syndrome and MCDmentioning

confidence: 99%

TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?

Takai

2024

Biomedicines

View full text Add to dashboard Cite

TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis of bone marrow/renal dysfunction, organomegaly) syndrome is a systemic inflammatory disorder of unknown etiology. It has been recognized as a subtype of idiopathic multicentric Castleman disease (iMCD), and the international diagnostic criteria for iMCD-TAFRO require a lymph node histopathology consistent with iMCD. Furthermore, TAFRO syndrome is defined as a heterogeneous clinical entity caused by underlying diseases such as malignancy, autoimmune diseases, or infections. However, the cases that led to the proposal of TAFRO syndrome lacked recognizable lymphadenopathy and were inconsistent with any other diseases, despite vigorous efforts in differential diagnosis. Irrespective of the presence or absence of Castleman disease (CD)-like histology, TAFRO syndrome exhibits homogeneous clinical, laboratory, and prognostic features, setting it apart from iMCD without TAFRO syndrome. Defining iMCD-TAFRO apart from TAFRO syndrome is deemed meaningless and confusing. MCD is a heterogeneous lymphoproliferative disorder consisting of several subtypes with different pathogenesis, clinical manifestations, and histological features. Typical MCD in Japan, characterized by the histology of plasma cell type and marked polyclonal hypergammaglobulinemia, is identical to idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL). Although IPL is classified into iMCD-NOS (not otherwise specified), it should be recognized as a distinct clinicopathological entity. Furthermore, we propose to separate TAFRO syndrome from the MCD category as a defined disorder.

show abstract

Historical and pathological overview of Castleman disease

Cited by 18 publications

References 73 publications

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease

TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?

Contact Info

Product

Resources

About